Etrasimod arginine. Sphingosine-1-phosphate receptor 1 (S1P1 receptor) agonist, Treatment of ulcerative colitis

2020 ◽  
Vol 45 (3) ◽  
pp. 165
Author(s):  
J. Gras

MedChemComm ◽  
2013 ◽  
Vol 4 (9) ◽  
pp. 1267 ◽  
Author(s):  
Yulin Tian ◽  
Jing Jin ◽  
Xiaojian Wang ◽  
Weijuan Han ◽  
Gang Li ◽  
...  


2014 ◽  
Vol 90 (1) ◽  
pp. 50-61 ◽  
Author(s):  
Jing Jin ◽  
Jinping Hu ◽  
Wanqi Zhou ◽  
Xiaojian Wang ◽  
Qiong Xiao ◽  
...  


2020 ◽  
pp. 91-101
Author(s):  
Sumona Bhattacharya Sumona Bhattacharya ◽  
Raymond K. Cross Raymond K. Cross

Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease, currently available therapies do not induce or maintain remission in >50% of patients. This underscores the need for additional therapies. In this review, the authors detail the novel therapies vedolizumab, tofacitinib, and ustekinumab and delve into therapies which may come onto the market within the next 10 years, including JAK-1 inhibitors (filgotinib and upadacitinib), IL-23 inhibitors (guselkumab, mirikizumab, and risankizumab), the anti-β4β7 and anti-βEβ7 integrin monoclonal antibody etrolizumab, the sphingosine-1-phosphate subtypes 1 and 5 modulator ozanimod, and mesenchymal stem cells. Further studies are required before these emerging therapies gain approval.



2006 ◽  
Vol 20 (4) ◽  
Author(s):  
Irina Gorshkova ◽  
Evgeny Berdyshev ◽  
Bahman Saatian ◽  
Yutong Zhao ◽  
Srikanth Pendyala ◽  
...  


2020 ◽  
Vol 131 (1) ◽  
pp. 85-94 ◽  
Author(s):  
Chun Dang ◽  
Yaoheng Lu ◽  
Qian Li ◽  
Chunyang Wang ◽  
Xiaofeng Ma


2012 ◽  
Vol 22 (8) ◽  
pp. 2794-2797 ◽  
Author(s):  
Qinghua Meng ◽  
Baowei Zhao ◽  
Qiongfeng Xu ◽  
Xuesong Xu ◽  
Guanghui Deng ◽  
...  


2014 ◽  
Vol 8 ◽  
pp. S213-S214 ◽  
Author(s):  
A. Olson ◽  
J. Hartung ◽  
G. Timony ◽  
R. Peach ◽  
M. Boehm ◽  
...  


2018 ◽  
Vol 120 (2) ◽  
pp. 1869-1877 ◽  
Author(s):  
Miao Xiong ◽  
Li Li ◽  
Yang Liu ◽  
Fangfang Zhou ◽  
Nana Shi ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document